High titre retroviral vector supernatant, produced in compliance with GMP, is a prerequisite for gene therapy purposes in clinical trials.

We have the ability and experience to produce retroviral vector supernatant on a small, medium and large scale covering demands for clinical phases I to III. This means that one produced lot of retroviral vector is sufficient for the treatment of more than 100 patients.

As an optional part of the downstream processing we offer a vector concentration step by tangential flow filtration to achieve higher concentration of infectious particles and a reduction in volume.

An extensive quality control program covering safety, purity and potency is performed on each production lot to ensure the specifications of our customers and the competent regulatory authorities are met.